The importance of acute kidney injury in suspected community acquired infection

PLoS One. 2019 May 7;14(5):e0216412. doi: 10.1371/journal.pone.0216412. eCollection 2019.

Abstract

Background: Most sepsis and acute kidney injury (AKI) cases are community acquired (CA). The aim of this study was to evaluate the characteristics of suspected community acquired infection (sCA-I) and CA-AKI and their impact upon patient outcomes.

Methods: All adult creatinine blood tests from non-elective, non-dialysis attendances to a single centre over a 29-month period were analysed retrospectively. We defined sCA-I and CA-AKI cases as antibiotic prescription and AKI alert within 48 hours of attendance respectively. Binary logistic regression models were created to determine associations with 30-day mortality, intensive care unit (ICU) admission and length of stay (LOS) dichotomised at median.

Results: Of 61,471 attendances 28.1% and 5.7% suffered sCA-I or CA-AKI in isolation respectively, 3.4% suffered both. sCA-I was present in 58.8% of CA-AKI cases and CA-AKI was present in 11.9% of CA-I cases. The combination of sCA-I and CA-AKI was associated with a higher risk for all outcomes compared to sCA-I or CA-AKI in isolation. The 30-day mortality was 8.1%, 11.8% and 26.2% in patients with sCA-I, CA-AKI and when sCA-I and CA-AKI occurred in combination respectively. The adjusted odds ratios (OR) and 95% confidence intervals (CI) for 30-day mortality, ICU admission and LOS for sCA-I combined with CA-AKI stage 1 were OR 6.09:CI: 5.21-7.12, OR 12.52 CI: 10.54-14.88 and OR 8.97 CI: 7.62-10.56, respectively, and for combined sCA-I and CA-AKI stage 3 were OR 9.23 CI: 6.91-12.33, OR 29.26 CI: 22.46-38.18 and OR 9.48 CI: 6.82-13.18 respectively.

Conclusion: The combination of sCA-I and CA-AKI is associated with worse outcomes.

Publication types

  • Clinical Trial

MeSH terms

  • Acute Kidney Injury* / mortality
  • Acute Kidney Injury* / therapy
  • Adult
  • Aged
  • Community-Acquired Infections* / mortality
  • Community-Acquired Infections* / therapy
  • Disease-Free Survival
  • Female
  • Hospital Mortality*
  • Humans
  • Intensive Care Units*
  • Length of Stay
  • Male
  • Middle Aged
  • Patient Admission
  • Sepsis / mortality
  • Sepsis / therapy
  • Survival Rate

Grants and funding

The authors received no specific funding for this work.